spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Zofran 

 HSMN NewsFeed - 10 Jul 2018
Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance
Biopharmaceuticals Product Recall
 HSMN NewsFeed - 2 Jul 2012
Glaxosmithkline Concludes Previously Announced Agreement in Principle to Resolve Multiple Investigations with US Government and Numerous States
Biopharmaceuticals
 HSMN NewsFeed - 18 Apr 2012
Aerocrine AB Announces New US Leadership
Devices Personnel
 HSMN NewsFeed - 20 Sep 2011
Tokai Pharmaceuticals Raises $23 Million in Funding
Biopharmaceuticals Personnel Venture Capital
 HSMN NewsFeed - 7 Jul 2010
MonoSol Rx Announces FDA Approval of Zuplenz(R) Oral Soluble Film for Treatment of Nausea and Vomiting
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 25 Mar 2008
Taro Receives FDA Approval for Ondansetron Hydrochloride Injection USP, 2 mg/mL ANDA
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 26 Jun 2007
Teva Announces Approval of Ondansetron HCl Tablets and Ondansetron Orally Disintegrating Tablets USP
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 26 Jun 2007
KV Pharmaceutical Company Receives ANDA Approval for 4 mg. and 8 mg. Ondansetron Orally Disintegrating Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 25 Jun 2007
Mylan Announces Final FDA Approval for Ondansetron Hydrochloride Tablets and Ondansetron Orally Disintegrating Tablets, USP
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 26 Feb 2007
Mylan Announces Tentative FDA Approval for Ondansetron Orally Disintegrating Tablets, USP
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 27 Dec 2006
Dr. Reddy's Announces Final Approval of Ondansetron Tablets with 180-Days of Marketing Exclusivity
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 26 Dec 2006
Hospira Launches Ondansetron Injection
Biopharmaceuticals Generics
 HSMN NewsFeed - 26 Dec 2006
Par Pharmaceutical Receives Approval for Ondansetron Orally Disintegrating Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 11 Jul 2006
FDA Approves EMEND(R) (aprepitant), Merck's Antiemetic Therapy, for the Prevention of Postoperative Nausea and Vomiting
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 25

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 25 additional stories matching:
Zofran
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.